Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Fineline Cube May 20, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Fineline Cube May 20, 2026
Company

MicroPort MedBot Reports Strong 2024 Growth for Toumai and SkyWalker Robots

Fineline Cube Mar 28, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) revealed its 2024 financial performance, recording RMB257...

Company Drug

Sanofi’s mRNA Chlamydia Vaccine Gains FDA Fast Track Designation

Fineline Cube Mar 27, 2025

French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving fast track designation from...

Company Deals Digital

Fangzhou Inc. Partners with Tencent Health to Advance AI-Driven Healthcare Solutions

Fineline Cube Mar 27, 2025

Guangzhou-based smart healthcare service platform Fangzhou Inc. (HKG: 6086) has announced a strategic partnership with...

Company Drug

Merck, Sharp & Dohme’s Capvaxive Approved by European Commission for Pneumococcal Prevention

Fineline Cube Mar 27, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the European Commission (EC)...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-9803 and SHR-A2102 Clinical Trials

Fineline Cube Mar 27, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...

Company Deals

Servier and Black Diamond Therapeutics Ink Global Deal for Solid Tumor Targeted Therapy BDTX-4933

Fineline Cube Mar 27, 2025

French pharmaceutical firm Servier has announced a global licensing agreement with US-based Black Diamond Therapeutics...

Company Deals Drug

Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization

Fineline Cube Mar 27, 2025

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s...

Company Drug

Shanghai Junshi Biosciences’ Loqtorzi Approved in Singapore for Nasopharyngeal Carcinoma

Fineline Cube Mar 27, 2025

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval from...

Company Drug

Zhejiang Funow Medicine Launches Triple Cream for Melasma Treatment in China

Fineline Cube Mar 27, 2025

China-based Zhejiang Fonow Medicine Co., Ltd. (formerly known as: Zhejiang Rishengchang Pharmaceutical Co., Ltd.) has...

Company Drug

Luye Pharma’s BA1302 Receives FDA Orphan Drug Designation for Lung and Pancreatic Cancer

Fineline Cube Mar 27, 2025

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...

Company Deals

Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&D with AI

Fineline Cube Mar 27, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into a collaboration with compatriot...

Company Deals

Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372

Fineline Cube Mar 27, 2025

German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe...

Company Drug

AstraZeneca’s Calquence Approved by NMPA for CLL/SLL Treatment

Fineline Cube Mar 27, 2025

UK pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving another indication approval from China’s National...

Company Medical Device

Shanghai ZJ Bio-Tech’s HCV Nucleic Acid Test Kit Receives NMPA Approval

Fineline Cube Mar 27, 2025

China-based molecular diagnostic reagent specialist Shanghai Liferiver Bio-Tech Co., Ltd (SHA: 688317) has announced receiving...

Company Deals

Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources

Fineline Cube Mar 27, 2025

China’s Shanghai RAAS (SHE: 002252) has announced plans to acquire 100% stakes in compatriot firm...

Company Drug

Sichuan Huiyu Pharmaceutical Wins Marketing Approvals in Italy, Portugal, Saudi Arabia

Fineline Cube Mar 27, 2025

China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) has announced its its subsidiaries Seacross Pharma...

Company Deals

Merck KGaA Partners with Roche to Commercialize Tepmetko in China

Fineline Cube Mar 26, 2025

Germany-based pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a partnership with Swiss giant...

Company Hospital

China Resources Medical Holdings Reports 2024 Revenue of RMB9.86 Billion Amid Net Profit Surge

Fineline Cube Mar 26, 2025

China Resources Medical Holdings Company Ltd (CR Medical, HKG: 1515) has published its 2024 financial...

Company Drug

GSK’s Blujepa Approved by FDA for Uncomplicated Urinary Tract Infections

Fineline Cube Mar 26, 2025

UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) announced that it has received marketing approval from...

Company Drug

Guangzhou Doublle Bioproduct Receives IND Approval for E101 in Type 2 Diabetes

Fineline Cube Mar 26, 2025

Guangzhou Doublle Bioproduct Co., Ltd. has announced receiving Investigational New Drug (IND) clearance from China’s...

Posts pagination

1 … 191 192 193 … 669

Recent updates

  • CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus
  • Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study
  • Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
  • Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
  • China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.